Comparison of a direct and indirect population pharmacodynamic model: Application to recombinant human erythropoietin in athletes

Journal of Pharmacokinetics and Biopharmaceutics

Volumn 25, Issue 3, 1997, Pages 263-275

  Bressolle, Françoise ^a   Audran, Michel ^a   Gareau, Raynald ^b   Pham, Tuyet Nga ^a   Gomeni, Roberto ^c  

^a UNIV MONTPELLIER   (France)

^b UNIVERSITÉ DU QUÉBEC À TROIS RIVIÈRES   (Canada)

^c BESTFIT   (Luxembourg)

Author keywords

Indirect response; Pharmacodynamics; Recombinant human erythropoietin; Sigmoid E(max) model

Indexed keywords

FERRITIN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN RECEPTOR;

ARTICLE; ATHLETE; COMPARTMENT MODEL; CONTROLLED STUDY; CURVE FITTING; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG RESPONSE; HUMAN; HUMAN EXPERIMENT; INTERMETHOD COMPARISON; MALE; NORMAL HUMAN; PHARMACODYNAMICS; PHYSIOLOGY; POPULATION MODEL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; ERYTHROPOIESIS; ERYTHROPOIETIN, RECOMBINANT; FERRITINS; HALF-LIFE; HUMANS; LINEAR MODELS; MALE; MATHEMATICAL COMPUTING; MODELS, BIOLOGICAL; RECEPTORS, TRANSFERRIN; REFERENCE VALUES; SPORTS;

EID: 0031442094     PISSN: 0090466X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1025737024403     Document Type: Article

References (16)

1. B. Berglund and B. Ekblom. Effect of recombinant human erythropoietin treatment on blood pressure and some haematological parameters in healthy males. J. Int. Med. 229:125-130 (1991).
2. B. Ekblom and B. Berglund. Effect of erythropoietin administration on maximal aerobic power in man. Scand. J. Med. Sci. Sports 1:88-93 (1991).
3. A. T. Kicman and D. A. Cowan. Peptides hormones and sport: Misuse and detection. Br. Med. Bull. 48:496-517 (1992).
4. M. J. Koury and M. C. Bondurant. The molecular mechanism of erythropoietin action. Eur. J. Biochem. 210:649-663 (1992).
5. W. Jelkman. Biology of erythropoietin. Clin. Invest. 72:S3-S10 (1994).
6. R. Gareau, M. Audran, R. D. Baynes, C. H. Flowers, A. Duvallet, L. Senécal, and G. R. Brisson. Erythropoietin abuse in athletes. Nature 380:113 (1996).
7. F. Bressolle, M. Audran, R. Gareau, R. D. Baynes, C. Guiolicelli, and R. Gomeni. Population pharmacodynamics for monitoring epoetin in athletes Clin. Drug. Invest. 14:233-242.
8. A. Souillard, M. Audran, F. Bressolle, R. Gareau, A. Duvallet, and J. L. Chanal. Recombinant human erythropoietin and pharmacodynamic parameters in athletes. Interest of blood sampling for doping control. Br. J. Clin. Pharmacol. 42:355-360 (1996).
9. L. B. Sheiner, D. R. Stanski, S. Vozeh, R. D. Miller, and J. Ham. Simultaneous modelling of pharmacokinetics and pharmacodynamics: Application to d-tubocurarine. Clin. Pharmacol. Ther. 25:358-371 (1979).
10. W. J. Jusko and H. C. Ko. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin. Pharmacol. Ther. 56:406-419 (1994).
11. N. L. Dayneka, V. Garg, and W. J. Jusko. Comparison of four basic models of indirect pharmacodynamic responses. J. Pharmacokin. Biopharm. 21:457-478 (1993).
12. D. V. Verotta and L. B. Sheiner. A general conceptual model for non-steady state pharmacokinetic/pharmacodynamic data. J. Pharmacokin. Biopharm. 23:1-4 (1995).
13. W. J. Jusko, H. C. Ko, and W. F. Ebling. Convergence of direct and indirect pharmacodynamic response models. J. Pharmacokin. Biopharm. 23:5-10 (1995).
14. L. Aarons. The estimation of population pharmacokinetic parameters using an EM algorithm. Comput. Meth. Prog. Biomed. 41:9-16 (1993).
15. EM-fit computer program, version 1.0, Bestfit, Luxembourg, 1996.
16. R. R. Sokal and J. R. N. Rohlf. Biometry, W. H. Freeman, San Francisco, 1969.